PMC:7534795 / 39680-40092
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T184 | 51-54 | Body_part | denotes | arm | http://purl.org/sig/ont/fma/fma24890 |
| T185 | 255-260 | Body_part | denotes | organ | http://purl.org/sig/ont/fma/fma67498 |
| T186 | 284-292 | Body_part | denotes | capsules | http://purl.org/sig/ont/fma/fma85272 |
| T187 | 317-322 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T66 | 51-54 | Body_part | denotes | arm | http://purl.obolibrary.org/obo/UBERON_0001460 |
| T67 | 255-260 | Body_part | denotes | organ | http://purl.obolibrary.org/obo/UBERON_0000062 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T317 | 104-112 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T263 | 51-54 | http://www.ebi.ac.uk/efo/EFO_0001410 | denotes | arm |
| T264 | 255-260 | http://purl.obolibrary.org/obo/UBERON_0003103 | denotes | organ |
| T265 | 317-322 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T299 | 141-145 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T300 | 158-171 | Chemical | denotes | dapagliflozin | http://purl.obolibrary.org/obo/CHEBI_85078 |
| T301 | 174-185 | Chemical | denotes | ambrisentan | http://purl.obolibrary.org/obo/CHEBI_135949 |
| T302 | 365-376 | Chemical | denotes | ambrisentan | http://purl.obolibrary.org/obo/CHEBI_135949 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T286 | 0-16 | Sentence | denotes | • TACTIC-E Trial |
| T287 | 17-71 | Sentence | denotes | • Immunomodulatory agents • Multi-arm randomized trial |
| T288 | 72-121 | Sentence | denotes | • Pre-intensive care unit (ICU) COVID-19 patients |
| T289 | 122-203 | Sentence | denotes | • Immunomodulatory drug EDP1815 vs. dapagliflozin + ambrisentan vs. standard care |
| T290 | 204-340 | Sentence | denotes | • Primary outcome includes need for cardiovascular organ support • EDP1815 as 2 capsules twice daily (1.6 × 1011 cells) for up to 7 days |
| T291 | 341-412 | Sentence | denotes | • Dapagliflozin 10 mg + ambrisentan 5 mg once daily (NCT04393246, 2020) |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1337 | 104-112 | Disease | denotes | COVID-19 | MESH:C000657245 |